Tag: HCV

In this issue the CCDR explores what we know about the Hepatitis C virus (HCV) in Canada. Since 1998, Canadian rates of reported HCV cases have declined over 50%, but certain populations remain at risk. An estimated 1% of people have been exposed to Hepatitis C in Canada. In our Useful Links section, find some… Read more »

CATIE’s HepCInfo Update 5.24

New and Noteworthy Harvoni cures 98% of Hep C and HIV co-infected participants with genotype 1 virus 98% of Hep C and HIV co-infected participants with genotype 1 virus who took Harvoni (ledipasvir + sofosbuvir) during a 12-week clinical trial were cured, reported researchers at the American Association for the Study of Liver Diseases (AASLD)… Read more »

PHAC: Release of HIV and HCV G&Cs Performance Reports

The Public Health Agency of Canada is pleased to share the first Federal Initiative to Address HIV/AIDS in Canada: National Grant and Contributions Performance Measurement Report – 2012-13 and the first Hepatitis C Prevention, Support and Research Program: National Grants and Contributions Performance Measurement Report – 2012-13. These reports summarize performance measurement findings for 2012-13,… Read more »

PHCN: Hepatitis C Treatment Information Project Update

The PHCN’s Hepatitis C Treatment Information Project was recently updated. New sections and pages were added to accommodate the ever growing wealth of information that the project now includes. For example, check out the newly rearranged Hep C Drug Pipeline page, which summarizes the treatments that are currently making their way through the hep C… Read more »

Janssen Inc.’s simeprevir, brand name Galexos, in combination with peginterferon/ribavirin was just approved by BC’s PharmaCare for the treatment of chronic hepatitis C genotype 1 in patients with or without compensated cirrhosis and who have: never tried to treat their hepatitis C OR tried treatment but the virus came back OR tried treatment but weren’t… Read more »

Fact Sheets: 2012 HIV/AIDS Attitudinal Tracking Survey

The Centre for Communicable Diseases and Infection Control of the Public Health Agency of Canada, commissioned the “2012 HIV/AIDS Attitudinal Tracking Survey”.  The final report (2012 Report) is currently available on the Library and Archives website. The report describes findings of the third cycle of a public opinion research study (previous cycles in 2003 and… Read more »

CATIE’s HepCInfo Update 5.19

New and Noteworthy CATIE-News: A hepatitis C outbreak among HIV-negative gay men in London, England Some HIV-negative gay men may be at risk for getting hepatitis C. Researchers from London, England found 44 cases of acute Hep C infection in HIV-negative gay men between 2010 and 2014. Among HIV-positive gay men, hepatitis C has been… Read more »

Take this survey It is 36, mostly multiple choice, questions that are divided into 5 sections. Sections that don’t pertain to you can be easily skipped. The survey’s 5 sections ask about: The impact of hep C on your life (8 questions) Your experience with current hep C treatments (9 questions) The impact on caregivers… Read more »

PHAC: Community Action Fund

On April 1, 2017, the Public Health Agency of Canada’s HIV and Hepatitis C Grants and Contributions funding programs will be integrated into a new funding program called the Community Action Fund. Over the past several months, the Agency has been exploring how best to deliver these funds to support a comprehensive community-based response to… Read more »

CATIE’s HepCInfo Update 5.17

New and Noteworthy Expanded harm reduction services decreased new Hep C infections in Scotland Implementing comprehensive harm reduction services averted an estimated 1400 new Hep C infections in Scotland, reported researchers in PLOS ONE. In 2008, the Scottish government expanded access to sterile injecting equipment, including needles, syringes, cookers, filters and water, and improved access… Read more »